New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2014
07:37 EDTRDS.A, COP, XOM, TOT, CVX, BPBig oil racing, and spending, to keep up, Businessweek reports
Major oil companies are spending more and producing less oil. Cheap, easy-to-find reserves are basically gone. To maintain production rates, oil companies are racing to find new reserves faster than the old ones dry up, reports Bloomberg Businessweek. Earning reports so far from big oil haven't been encouraging. Reference Link
News For A;CVX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 28, 2015
08:38 EDTAAgilent authorizes repurchase of up to $1.14B of common stock
Agilent Technologies announced that its board of directors has approved a new share repurchase program. The 2015 Stock Repurchase Program authorizes the purchase of up to $1.14B of the company’s common stock through and including Nov. 1, 2018. The new program will commence, at the option of the company, on either Nov. 1, 2015, or the date on which the company completes the purchase of $365M of common stock under the existing stock repurchase program in fiscal 2015. Upon commencement, the new repurchase program replaces Agilent’s existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs.
May 27, 2015
13:02 EDTCVXChevron says plans to reduce capital spending
Chevron provided an overview of the company’s 2014 operational and social performance and how the company is managing through current market conditions at its 2015 Annual Meeting of Stockholders in San Ramon, California. “We have the financial strength to meet the challenges of a volatile crude price environment and significant efforts are underway to manage to a lower cost structure and capital spend rate,” said John Watson, chairman of the board and CEO. “We’re reducing capital spending, we have implemented significant cost-reduction programs and have further streamlined our portfolio as planned.” The company informed stockholders on its commitment to safety, noting that 2014 was Chevron’s best year on every key measure of personal safety, process safety and environmental performance.
10:14 EDTCVXAnalyst says China trend good for oil equities
China's demand for oil has been stronger than expected and the trend should be positive for oil companies' stocks, research firm Bernstein wrote in a note to investors today. WHAT'S NEW: Chinese oil imports reached a record high in April, rising 9% versus the same period a year earlier, Bernstein analyst Neil Beveridge reported. The imports have exceeded expectations and have been boosted by high gasoline demand, according to the analyst. The high gasoline demand in China, in turn, has been driven by a 50% year-over-year increase in the sales of SUVs, according to Beveridge. Analysts will respond to this trend by increasing their global oil demand estimates, he predicted. Oil prices are likely to rise in the near-term, providing a tailwind for oil equities, according to Beveridge, who identified InterOil (IOC) and China's CNOOC (CEO) as two of his favorite names in the Asian region. Other publicly traded companies in the oil space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). WHAT'S NOTABLE: Jaguar Land Rover, owned by India's Tata Motors (TTM), is launching its Range Rover Evoque SUV in China this fiscal year, but is having trouble ramping up production of the vehicle, Forbes reported last week. PRICE ACTION: in early trading, CNOOC was flat at $162.50 and InterOil slipped fractionally to $46.58.
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
07:26 EDTCVXUBS to hold a conference
Subscribe for More Information
May 19, 2015
09:37 EDTCVXActive equity options trading on open
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
10:01 EDTCVXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:36 EDTCVXActive equity options trading on open
Subscribe for More Information
09:20 EDTCVXW.R. Grace, Chevron JV to build catalysts plant in Lake Charles, LA
Subscribe for More Information
07:56 EDTCVXKosmos provides update on Mauritania drilling
Subscribe for More Information
07:23 EDTCVXChevron downgraded to Sell from Neutral at Goldman
Subscribe for More Information
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
06:44 EDTCVXEnvironmentalists file lawsuit over oil train safety rules, NY Times says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use